Related Experiment Video

Updated: Oct 2, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Oncolytic Vaccinia Virus in Lung Cancer Vaccines

Cao-Sang Truong1, So Young Yoo1

  • 1BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Korea.

Vaccines
|February 26, 2022
PubMed

Insights

Therapeutic cancer vaccines using vaccinia virus (VV) show promise for treating non-small cell lung cancer (NSCLC) by stimulating long-term immune responses. This review explores VV

Area of Science:

  • Oncology
  • Immunology
  • Virology

Background:

  • Therapeutic cancer vaccines offer a promising approach to cancer treatment by inducing sustained immune responses and minimizing side effects through targeted tumor antigen recognition.
  • Oncolytic viruses, particularly vaccinia virus (VV), are emerging as potent tools for cancer immunotherapy and can be developed into effective cancer vaccines.
  • Non-small cell lung cancer (NSCLC) exhibits a high tumor mutational burden, suggesting a favorable response to immunotherapies like immune checkpoint inhibitors and cancer vaccines.

Purpose of the Study:

  • To review the recent applications of vaccinia virus (VV) in the treatment of lung cancer.
  • To discuss the potential and future directions for developing VV-based therapeutic cancer vaccines for NSCLC.

Main Methods:

  • Literature review of recent studies on vaccinia virus in lung cancer treatment.
  • Analysis of the potential of VV as a platform for therapeutic cancer vaccines.
  • Discussion of immunotherapy strategies for non-small cell lung cancer.

Main Results:

  • Vaccinia virus (VV) has demonstrated potential as a therapeutic agent and vaccine platform for lung cancer.
  • Recent research highlights the efficacy of VV in preclinical and clinical settings for cancer immunotherapy.
  • The high tumor mutational burden in NSCLC indicates a strong potential for response to VV-based vaccines.

Conclusions:

  • Vaccinia virus (VV) holds significant promise as a component of therapeutic cancer vaccines for non-small cell lung cancer (NSCLC).
  • Further research and development are warranted to optimize VV-based vaccine strategies for improved lung cancer treatment outcomes.
  • VV-based vaccines represent a viable and potentially effective immunotherapy approach for NSCLC, leveraging the virus's oncolytic and immunomodulatory properties.
Keywords:
cancer vaccineimmunotherapynon-small cell lung canceroncolytic viruspersonalized vaccinationvaccinia virus

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.4K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
542
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
708
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.4K